$0.29 to $50+ Why NWBO Will 100X on Approval This Year (Full DD Video + Lawsuit Update)
🚀Join the FREE Discord (for a limited time only) here: https://go.teamalphatrading.com/mikes...
🎯Grab Your Text Alerts + Congressional & Insider Trade Alerts Here https://go.teamalphatrading.com/texta...
⚠️ (1 on 1 Training is SOLD OUT) If you wanna join my next round of students and get 1 on 1 training from me and my team of coaches join the waitlist here:
https://go.teamalphatrading.com/1on1w...
🎯My NEW YouTube Channel: / @itsmikepoarch
🤵 Mike's Twitter: / itsmikepoarch
🤑Mike's Instagram: / itsmikepoarch
💰Mike's TikTok: https://www.tiktok.com/@itsmikepoarch...
⚠️Mike's Facebook: / mikewithalphastatus
🤑Get a bunch of FREE stocks on Webull by signing up with my link (my FAVORITE broker / trading app): https://a.webull.com/i/AlphaStatusStocks
Northwest Biotherapeutics, Inc is a clinical stage biotechnology company focused on the development of personalized cancer vaccines designed to treat a broad range of solid tumor cancers. DCVax® is a platform technology that uses activated dendritic cells (the master cells of the immune system), and is designed to reinvigorate and educate the immune system to attack cancers. Unlike conventional cancer drugs, which use one active agent to hit one target on the cancer, DCVax uses many active agents to hit many targets on the cancer. DCVax is designed to mobilize the entire immune system, not just one among the many different categories of immune agents in that overall system. DCVax is designed to target not just one but the full set of biomarkers on the patient’s tumor. DCVax is personalized, and targets the particular biomarkers expressed on that patient’s tumor. The DCVax technology is expected to be applicable to most cancers, and is embodied in several distinct product lines. One of the product lines (DCVax®-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed.
References used in presentation:
Northwest Biotherapeutics Official Press Release
Cancer Immunotherapy Market Analysis
Details on Flaskworks Technology
SEC Filing on NWBO’s Lawsuit
Northwest Biotherapeutics Official Press Release on Phase 3 Results
FDA’s Overview of Immunotherapy in Cancer
Clinical Trials.gov: DCVax-L Phase 3 Results
National Cancer Institute – Immunotherapy Explained
FDA’s Overview of Personalized Cancer Vaccines
United States Patent and Trademark Office (USPTO)
European Patent Office (EPO)
Evaluate.com
FierceBiotech.com
CNBC.com
GlobalData.com
ResearchandMarkets.com
Disclaimer: We are not Financial advisers. These videos are for entertainment purposes only. These videos are not meant to substitute a professional of any field. We are not invested into every company we talk about. This Presentation may not be 100% Correct, this is for introductory and unofficial material. Any results discussed in this video (or on this channel) are not typical. Day trading is risky, and most traders lose money. We do not track the typical results of past or current customers. As a provider of trading tools and educational courses, we do not have access to the personal trading accounts or brokerage statements of our customers. As a results, we have no reason to believe our customers perform better or worse than traders as a whole. You understand, acknowledge and agree that, For informational and teaching purposes only, trades may be called out, posted, or alerted, but not executed. It is important to understand that trading outcomes vary widely and are not typical. While some individuals may achieve significant profits, most traders incur losses. Factors such as market volatility, economic conditions, and individual trading strategies can impact results. Before engaging in any trading activity, it is essential to carefully consider your financial situation, risk tolerance, and investment objectives. It is recommended to consult with a qualified financial advisor or professional before making any trading decisions. By accessing this information, you acknowledge that trading involves inherent risks, and you are solely responsible for any trades you undertake. You agree to not hold the provider of this information liable for any losses incurred as a result of your trading activities. You understand, acknowledge, and agree that the Site contains simulated or hypothetical trading. No representation is being made that any account will or is likely to achieve profits or losses similar to these being shown. We may receive incentives by clicking our links. Read Alpha Status full disclaimer here: https://1drv.ms/w/s!AgEcA6DFihbCeb2iD...
